Artal Group S.A. purchased a new position in Twist Bioscience Corp (NASDAQ:TWST) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 150,000 shares of the company’s stock, valued at approximately $3,464,000. Artal Group S.A. owned approximately 0.54% of Twist Bioscience at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Dean Capital Investments Management LLC bought a new stake in Twist Bioscience during the fourth quarter valued at about $990,000. Victory Capital Management Inc. purchased a new stake in Twist Bioscience in the fourth quarter valued at about $1,711,000. Emerald Mutual Fund Advisers Trust purchased a new stake in Twist Bioscience in the fourth quarter valued at about $3,118,000. Emerald Advisers LLC purchased a new stake in Twist Bioscience in the fourth quarter valued at about $3,804,000. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of Twist Bioscience in the fourth quarter worth about $5,068,000. 22.56% of the stock is currently owned by institutional investors.
Twist Bioscience stock traded up $0.38 during trading on Thursday, reaching $21.44. 22,600 shares of the company were exchanged, compared to its average volume of 71,660. Twist Bioscience Corp has a 52-week low of $12.38 and a 52-week high of $34.46. The company has a market cap of $590.10 million and a price-to-earnings ratio of -0.84. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.43 and a current ratio of 7.72.
Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, February 7th. The company reported ($1.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.33). The company had revenue of $11.49 million during the quarter, compared to analysts’ expectations of $9.70 million. On average, analysts predict that Twist Bioscience Corp will post -4.18 EPS for the current fiscal year.
Several research firms recently commented on TWST. Zacks Investment Research raised Twist Bioscience from a “sell” rating to a “hold” rating in a report on Thursday, February 28th. JPMorgan Chase & Co. initiated coverage on Twist Bioscience in a report on Monday, November 26th. They issued a “neutral” rating and a $27.00 price objective on the stock. Robert W. Baird initiated coverage on Twist Bioscience in a report on Monday, November 26th. They issued an “outperform” rating on the stock. Finally, Cowen initiated coverage on Twist Bioscience in a research note on Monday, November 26th. They issued an “outperform” rating on the stock.
Twist Bioscience Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
See Also: Buyback
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.